Antibody drug conjugates (ADCs) deliver highly potent chemotherapy agents directly to cancer cells via a linker attached to a targeted antibody. Unlock the potential of ADCs with our comprehensive services and solutions.
Leveraging advanced technology, Eurofins CDMO adeptly manages diverse batch sizes. With 200 L fed-batch and perfusion capabilities, Eurofins CDMO is dedicated to the development and scaling of monoclonal antibodies (mAbs), and supports programmes from early-stage research development through late-stage GMP operations.
Designing robust and scalable processes with quality embedded into the entire product lifecycle, we deliver fully integrated solutions for ADC production by consolidating deep expertise in linker and warhead development with a state-of-the-art GMP biologics manufacturing capacity.
With our deep expertise in linker-payload development, we can produce a linker tailored to your drug programme.
Leveraging our established expertise in small molecule manufacturing, we provide tailored solutions for linker and payload synthesis, with capacity for Highly Potent Active Pharmaceutical Ingredients (HPAPIs). This capability ensures seamless integration of the linker-payload and ADC manufacturing processes.
Our team is experienced in carrying out stochastic and site-specific conjugations with a range of linker-payloads and conjugation chemistries. Our team has a proven track record delivering on challenges such as the production of multi-payload (more than one type of payload) constructs using high potency payloads, as well as successfully achieving target ADC DARs for our clients.
